| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A platinum age for rheumatology
|
The Lancet,
|
|
2017
|
389 |
10086 |
p. 2263-
1 p.
|
article
|
| 2 |
Body-mass index and all-cause mortality
|
Flegal, Katherine M
|
|
2017
|
389 |
10086 |
p. 2284-2285
2 p.
|
article
|
| 3 |
Body-mass index and all-cause mortality
|
Angadi, Siddhartha S
|
|
2017
|
389 |
10086 |
p. 2285-
1 p.
|
article
|
| 4 |
Body-mass index and all-cause mortality
|
Pepper, Dominique J
|
|
2017
|
389 |
10086 |
p. 2284-
1 p.
|
article
|
| 5 |
Body-mass index and all-cause mortality – Authors' reply
|
Di Angelantonio, Emanuele
|
|
2017
|
389 |
10086 |
p. 2285-2286
2 p.
|
article
|
| 6 |
Cholera outbreak in Haiti—from 2010 to today
|
Zarocostas, John
|
|
2017
|
389 |
10086 |
p. 2274-2275
2 p.
|
article
|
| 7 |
Cyclone Mora devastates south Asia
|
Sharma, Dinesh C
|
|
2017
|
389 |
10086 |
p. 2273-
1 p.
|
article
|
| 8 |
Data sharing statements for clinical trials: a requirement of the International Committee of Medical Journal Editors
|
Taichman, Darren B
|
|
2017
|
389 |
10086 |
p. e12-e14
nvt p.
|
article
|
| 9 |
Department of Error
|
|
|
2017
|
389 |
10086 |
p. 2286-
1 p.
|
article
|
| 10 |
Dupilumab for atopic dermatitis
|
Strowd, Lindsay C
|
|
2017
|
389 |
10086 |
p. 2265-2266
2 p.
|
article
|
| 11 |
EULAR: Countries unite to fight rheumatic diseases
|
Rubin, Rita
|
|
2017
|
389 |
10086 |
p. 2276-
1 p.
|
article
|
| 12 |
Galileo—speaking truth to power
|
Marmot, Michael
|
|
2017
|
389 |
10086 |
p. 2277-2278
2 p.
|
article
|
| 13 |
Gerd Burmester: enduring leader in rheumatoid arthritis
|
Lane, Richard
|
|
2017
|
389 |
10086 |
p. 2279-
1 p.
|
article
|
| 14 |
Herbert Barrie
|
Watts, Geoff
|
|
2017
|
389 |
10086 |
p. 2282-
1 p.
|
article
|
| 15 |
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
|
Nash, Peter
|
|
2017
|
389 |
10086 |
p. 2317-2327
11 p.
|
article
|
| 16 |
James Hardy and the first heart transplant
|
Morris, Thomas
|
|
2017
|
389 |
10086 |
p. 2280-2281
2 p.
|
article
|
| 17 |
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
|
Blauvelt, Andrew
|
|
2017
|
389 |
10086 |
p. 2287-2303
17 p.
|
article
|
| 18 |
New ACMD regulations threaten UK's pharmaceutical discovery
|
Nutt, David
|
|
2017
|
389 |
10086 |
p. 2283-
1 p.
|
article
|
| 19 |
New pathways of treatment for psoriatic arthritis
|
Mease, Philip
|
|
2017
|
389 |
10086 |
p. 2268-2270
3 p.
|
article
|
| 20 |
Novel treatment strategies in rheumatoid arthritis
|
Burmester, Gerd R
|
|
2017
|
389 |
10086 |
p. 2338-2348
11 p.
|
article
|
| 21 |
Offline: Sweden seeks a renaissance in global health
|
Horton, Richard
|
|
2017
|
389 |
10086 |
p. 2272-
1 p.
|
article
|
| 22 |
Pathogenetic insights from the treatment of rheumatoid arthritis
|
McInnes, Iain B
|
|
2017
|
389 |
10086 |
p. 2328-2337
10 p.
|
article
|
| 23 |
Renewed push to strengthen vector control globally
|
Alonso, Pedro
|
|
2017
|
389 |
10086 |
p. 2270-2271
2 p.
|
article
|
| 24 |
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
|
Jørgensen, Kristin K
|
|
2017
|
389 |
10086 |
p. 2304-2316
13 p.
|
article
|
| 25 |
The switch to infliximab biosimilars
|
Veselý, Richard
|
|
2017
|
389 |
10086 |
p. 2266-2268
3 p.
|
article
|
| 26 |
Time to talk about menstruation: #PeriodEmoji
|
The Lancet,
|
|
2017
|
389 |
10086 |
p. 2264-
1 p.
|
article
|
| 27 |
When childhood is stolen
|
The Lancet,
|
|
2017
|
389 |
10086 |
p. 2264-
1 p.
|
article
|
Journal description